No 10Y consistency score yet for revenue — the window needs more comparable quarters.
Valuation vs own 10Y history: P/S 973.1x · 10Y median 2950.2x · 3rd percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 12
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T12:45:56.210Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for CG Oncology Inc. (CGON) stock was $68.71 as of Oct 5, 2026, 4:00 PM EDT, up 1.97% from the previous close.
Longer view (total return, dividends reinvested): past 12 months +72.1%
CG Oncology, Inc., a late-stage clinical biopharmaceutical company, develops and commercializes cretostimogene grenadenorepvec for patients with bladder cancer in the United States. The company’s product candidate is cretostimogene, an investigational oncolytic immunotherapy, which is in phase 2 clinical trials of cretostimogene in patients with high-risk NMIBC after BCG failure; a phase 3 clinical trials to evaluate the safety and efficacy of cretostimogene as monotherapy in the treatment of patients who have received adequate BCG therapy with high-risk BCG-unresponsive, CIS-containing NMIBC and BCG-unresponsive Ta, or T1 papillary tumors; phase 3 BOND-003 Cohort C trials as a single agent; phase 3 BOND-003 Cohort P as a single agent in patients with BCG-UR papillary-only NMIBC.
Biotechnology · Dallas, TX
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 13, 2026
38 days away
EPS Estimate
-0.86
Revenue Est.
$547684.00
Last Quarter Results
EPS
$-0.90
vs Estimate
$-0.64
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1CGON | $6.06B | $68.71 | +1.97% | +72.10% | N/A | N/A | N/A |
| 2AMRX | $6.50B | $20.35 | +0.25% | +95.23% | +30.25% | -1.73% | vs CGON |
| 3CRSP | $5.53B | $57.34 | +3.45% | -15.29% | -10.97% | N/A | vs CGON |
| 4GRAL | $6.61B | $154.08 | +7.55% | +134.10% | N/A | N/A | vs CGON |
| 5HIMS | $6.62B | $29.67 | +2.31% | -43.37% | +32.23% | N/A | vs CGON |
| 6CHE | $6.68B | $511.30 | +0.75% | +15.83% | +3.58% | +14.19% | vs CGON |
forward FY estimate
N/A
$1.16M
vs Estimate
$360805.00
Consensus Rating
Based on 13 analysts
Average Price Target
$91.08
+32.6% upside
Low
$79.00
Current
$68.71
High
$108.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.93 | $-0.83 | $-0.64 | 9 |
| Quarter ending Dec 2026 | $-0.97 | $-0.85 | $-0.70 | 9 |
| Quarter ending Mar 2027 | $-2.86 | $-0.91 | $0.08 | 6 |
| Quarter ending Jun 2027 | $-2.70 | $-0.86 | $0.07 | 3 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-3.61 | $-3.32 | $-3.10 | 11 |
| FY 2027 | $-3.64 | $-3.13 | $-2.16 | 11 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $507114.00 | $547684.00 | $588253.00 | 7 |
| Quarter ending Dec 2026 | $86278.00 | $522850.00 | $1.38M | 7 |
| Quarter ending Mar 2027 | $4.13M | $25.00M | $66.05M | 3 |
| Quarter ending Jun 2027 | $1.87M | $11.32M | $29.92M | 3 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $1.53M | $4.32M | $12.50M | 10 |
| FY 2027 | $9.03M | $80.63M | $148.14M | 10 |
